Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05964920
Other study ID # TESTO-MEM
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date January 1, 2024
Est. completion date July 30, 2025

Study information

Verified date November 2023
Source Norwegian School of Sport Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project's primary aim of this double-blinded, randomised, placebo-controlled trial is to investigate whether short-term testosterone administration +/- resistance exercise training induces a muscle memory response that can lead to longer-lasting benefits in aged human skeletal muscle. The investigators will provide older men with the anabolic hormone, testosterone or placebo, with or without resistance training, followed by a period of testosterone abstinence and detraining, followed by a subsequent repeated period of resistance training (retraining). This will help determine if earlier encounters with short-term testosterone administration can be "remembered" and if adaptation to later retraining can be enhanced as a consequence of encountering testosterone earlier.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date July 30, 2025
Est. primary completion date July 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 55 Years to 70 Years
Eligibility Inclusion Criteria: - Sedentary males - 55-70 years old - Serum testosterone levels >8 nmol/L measured in the morning - Without any known illness, disease or other conditions - Undergone screening through medical questionnaire, physical examination, routine blood tests and urine sample - Written informed consent received Exclusion Criteria: - Current or previous participation in a formal exercise regime - A BMI < 18 or > 30 kg·m2 - Hypersensitivity to the study drug or to any of its constituents - Active cardiovascular disease: uncontrolled hypertension (BP > 160/100 mmHg), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event - Family history of early (<55y) death from cardiovascular disease - Haematocrit >50% - Malignancy - Prostate-specific antigen (PSA) >4 ng/mL - Lower urinary tract symptoms - Taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs - Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial), epilepsy - Respiratory diseases including: pulmonary hypertension, chronic obstructive pulmanary disease (COPD), asthma, sleep apnoea - Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes - Active inflammatory bowel or renal disease - Current or previous steroid treatment or hormone replacement therapy - Clotting dysfunction - Musculoskeletal or neurological disorders - Alcohol or drug abuse - Receiving oral anticoagulants - Serum testosterone levels above the reference range for 50 year olds (>32 nmol/L) (Bjerner et al., 2009) measured in the morning 1

Study Design


Intervention

Drug:
Saline
Two placebo injections one at baseline and one week 3.
Testosterone Undecanoate
Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
Saline + Resistance exercise training
Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
Testosterone Undecanoate + Resistance exercise training
Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Norwegian School of Sport Sciences Oslo University Hospital

References & Publications (7)

Egner IM, Bruusgaard JC, Eftestol E, Gundersen K. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. J Physiol. 2013 Dec 15;591(24):6221-30. doi: 10.1113/jphysiol.2013.264457. Epub 2013 Oct 28. — View Citation

Gharahdaghi N, Rudrappa S, Brook MS, Idris I, Crossland H, Hamrock C, Abdul Aziz MH, Kadi F, Tarum J, Greenhaff PL, Constantin-Teodosiu D, Cegielski J, Phillips BE, Wilkinson DJ, Szewczyk NJ, Smith K, Atherton PJ. Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men. J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1276-1294. doi: 10.1002/jcsm.12472. Epub 2019 Sep 30. — View Citation

Seaborne RA, Strauss J, Cocks M, Shepherd S, O'Brien TD, van Someren KA, Bell PG, Murgatroyd C, Morton JP, Stewart CE, Sharples AP. Human Skeletal Muscle Possesses an Epigenetic Memory of Hypertrophy. Sci Rep. 2018 Jan 30;8(1):1898. doi: 10.1038/s41598-018-20287-3. — View Citation

Sharples AP, Polydorou I, Hughes DC, Owens DJ, Hughes TM, Stewart CE. Skeletal muscle cells possess a 'memory' of acute early life TNF-alpha exposure: role of epigenetic adaptation. Biogerontology. 2016 Jun;17(3):603-17. doi: 10.1007/s10522-015-9604-x. Epub 2015 Sep 8. — View Citation

Sharples AP, Turner DC. Skeletal muscle memory. Am J Physiol Cell Physiol. 2023 Jun 1;324(6):C1274-C1294. doi: 10.1152/ajpcell.00099.2023. Epub 2023 May 8. — View Citation

Turner DC, Seaborne RA, Sharples AP. Comparative Transcriptome and Methylome Analysis in Human Skeletal Muscle Anabolism, Hypertrophy and Epigenetic Memory. Sci Rep. 2019 Mar 12;9(1):4251. doi: 10.1038/s41598-019-40787-0. — View Citation

Wen Y, Dungan CM, Mobley CB, Valentino T, von Walden F, Murach KA. Nucleus Type-Specific DNA Methylomics Reveals Epigenetic "Memory" of Prior Adaptation in Skeletal Muscle. Function (Oxf). 2021 Aug 5;2(5):zqab038. doi: 10.1093/function/zqab038. eCollection 2021. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Skeletal muscle stiffness Change and differences in skeletal muscle stiffness measured by shear wave ultrasonography Baseline and weeks 10, 22, 32
Other Skeletal muscle tissue characteristics Change and differences in skeletal muscle tissue characteristics determined by immunohistochemistry of muscle biopsies Baseline and weeks 10, 22, 32
Other Bone mineral density Change and differences in bone mineral density (g/cm2) measured by DEXA Baseline and weeks 10, 22, 32
Other Bone health Change and differences in bone health determined by bone health biomarkers in blood Baseline and weeks 10, 22, 32
Other Blood parameters Change and differences in steroid hormones in blood (testosterone, androstenediol, estradiol, and other relevant steroid markers, reproductive hormones (LH, FSH), binding protein (SHBG), cholesterol (total cholesterol, LDL, HDL), and PSA level, and endocrine biomarkers (IGF-1 and P-III-NP). Baseline and weeks 10, 22, 32
Other Aging males symptoms Change and differences in Aging male symptoms score (1="none", 5="extremely severe") Baseline and weeks 5, 10, 16, 22, 27, 32
Other Well-being Change and differences in WHO5 well-being index score (0="at not time", 5="all of the time") Baseline and weeks 5, 10, 16, 22, 27, 32
Other Psychological distress Change and differences in SCL-10 symptoms score (1="not at all", 4="extremely") Baseline and weeks 5, 10, 16, 22, 27, 32
Other Fatigue Change and differences in shortened fatigue questionnaire score (1="yes, that is true", 7="no, that is not true") Baseline and weeks 5, 10, 16, 22, 27, 32
Other Sleep Change and differences in Jenkins sleep scale score (0="not at all", 5="22-31days") Baseline and weeks 5, 10, 16, 22, 27, 32
Other Sexual function Change and differences in sexual function score (items from Health-related quality of life (HRQOL) questionnaire), ( Baseline and weeks 5, 10, 16, 22, 27, 32
Other Body perception Change and differences in Body Perception Questionnaire very short form score (1=never, 5=always) Baseline and weeks 5, 10, 16, 22, 27, 32
Other Anger Change and differences in The State Anger subscale of STAXI-2score (0="not at all", 3="very much") Baseline and weeks 5, 10, 16, 22, 27, 32
Other Mania Change and differences in Altman Self-Rating Mania Scale (ASRM) score Baseline and weeks 5, 10, 16, 22, 27, 32
Other Suicide thoughts Change and differences in Suicide thoughts from Montgomery and Åsberg Depression Rating Scale Baseline and weeks 5, 10, 16, 22, 27, 32
Other Cognitive function Change and differences in cognitive function measured by rapid visual information processing Baseline and weeks 5, 10, 16, 22, 27, 32
Other Raadiness to train Change and differences in readiness to train questionnaire score Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Other Exercise effort Change and differences in rating of perceived exertion for effort (Borg CR-10 RPE) Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Other Exercise discomfort Change and differences in rating of perceived exertion for discomfort (sRPD) score Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Other Session pleasure and displeasure Change and differences in perceived pleasure/displeasure with the training session using the pleasure/displeasure feeling scale (sPDF), (-5=very bad", 5="very good") Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Other Exercise enjoyment Change and differences in exercise enjoyment scale score (1="not at all", 7=extraordinary") Baseline and weekly up to week 10, and weekly from week 22 up to week 32
Primary Fat-free mass Change and differences in fat-free mass (g) measured by dual x-ray absorptiometry (DEXA). Baseline and weeks 10, 22, 32
Primary Skeletal muscle size and cross-sectional area (CSA) Change and differences in skeletal muscle size and CSA measured by ultrasound Baseline and week 5,10, 16, 22, 27, 32
Primary Skeletal muscle fibre CSA Change and differences in skeletal muscle fibre CSA measure determined by immunohistochemistry Baseline and weeks 10, 22, 32
Secondary DNA methylation in skeletal muscle and blood Methylation measured in difference/fold change values relative to appropriate controls. Baseline and weeks 10, 22, 32
Secondary Gene expression in skeletal muscle and blood Gene expression measured in difference/fold change values relative to appropriate controls. Baseline and weeks 10, 22, 32
Secondary Myonuclei Change and differences in number of myonuclei determined by immunohistochemistry Baseline and weeks 10, 22, 32
Secondary Satellite cells Change and differences in number of satellite cells determined by immunohistochemistry Baseline and weeks 10, 22, 32
Secondary Isometric muscle strength Change and differences in peak muscle strength (N) using isokinetic dynamometry Baseline and weeks 5, 10, 16, 22, 27, 32
Secondary Dynamic muscle strength Change and differences in 1-repetition maximum Baseline and weeks 5, 10, 16, 22, 27, 32
Secondary Muscle force-velocity profiling Change and differences in force (N) and velocity (m/s) derived from a 10-repetition FV-test Baseline and weeks 5, 10, 16, 22, 27, 32
See also
  Status Clinical Trial Phase
Recruiting NCT05596474 - Effect of Beet-root Juice and PBM Treatments on Muscle Fatigue N/A
Active, not recruiting NCT05203848 - Community Dance Program (CDP) for Older Adults Phase 1
Not yet recruiting NCT06455982 - Reduced Carbohydrates + Ketogenic Supplement on Energy Metabolism N/A
Completed NCT04084457 - Investigating the Effects of Daily Consumption of Blueberry (Poly)Phenols on Vascular Function and Cognitive Performance N/A
Recruiting NCT05006261 - A Mobile Tai Chi Platform for Fall Prevention in Older Adults - Phase II N/A
Active, not recruiting NCT04262674 - Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older Adults N/A
Completed NCT02218411 - Video-supported Group-based Otago Exercise Programme on Physical Performance in Older Adults. Phase 1
Active, not recruiting NCT05961319 - Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults
Completed NCT05213091 - The Effect of Otago Exercises in the Elderly N/A
Active, not recruiting NCT04904068 - Functional Neuroimaging in Parkinson's Disease
Completed NCT04348162 - Food Anthocyanins and Flavanols as a Strategy for a Healthy Ageing: Cardiovascular Health and Cognitive Performance N/A
Completed NCT05941143 - Effect of Mindfulness on EEG Brain Activity for Cognitive and Psychological Well-being in the Elderly N/A
Completed NCT06022094 - Effect of a Two-month Carbohydrate-restricted Diet on Energy Metabolism in a Seniors' Residence N/A
Active, not recruiting NCT06162871 - Social Participation and Healthy Aging N/A
Completed NCT05207501 - Effects of Different Moderate-intensity Exercise Methods on Health in the Elderly N/A
Recruiting NCT04986787 - Novel, Individualized Brain Stimulation, Network-based Approaches to Improve Cognition N/A
Completed NCT05933798 - China Pilot of ICOPE (Integrated Care for Older People) in Chaoyang N/A
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Completed NCT04786665 - Strawberries, Cognition, and Vascular Health N/A
Completed NCT05290571 - Modified Otago Exercise Program on Balance Performance N/A